Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio PR NewswireNeurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal statnews.comNeurocrine expands into metabolic diseases with $2.9 billion Soleno buyout CNBCNeurocrine wants to develop new obesity drugs. It’s spending $2.9 billion on a company to accelerate that move. MarketWatchNeurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout Fierce Pharma
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PR Newswire
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio PR NewswireNeurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal statnews.comNeurocrine expands into metabolic diseases with $2.9 billion Soleno buyout CNBCNeurocrine wants to develop new obesity drugs. It’s spending $2.9 billion on a company to accelerate that move. MarketWatchNeurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout Fierce Pharma
Source: Google News Business EN .
